Table 1 Clinical characteristics.
Characteristics | CDOX | Doxil | Myocet | Total |
|---|---|---|---|---|
Patient age, years | ||||
 Mean | 49.24 | 57.37 | 54.64 | 50.14 |
 < 18, n (%) | 650 (1.77) | 9 (0.21) | 3 (0.96) | 662 (1.60) |
 18–64, n (%) | 3321 (9.05) | 378 (8.96) | 9 (2.87) | 3708 (8.99) |
 ≥ 65, n (%) | 1174 (3.20) | 181 (4.29) | 14 (4.46) | 1369 (3.32) |
 Unknown | 31,570 (85.99) | 3653 (86.54) | 288 (91.72) | 35,511 (86.09) |
Wt, kg | ||||
 Mean | 57.68 | 72.22 | 70.80 | 59.61 |
Reporting country, n (%) | ||||
 Austria | 244 (0.66) | 70 (1.66) | 18 (5.73) | 332 (0.80) |
 Canada | 2895 (7.89) | 320 (7.58) | (0) | 3215 (7.79) |
 China | 798 (2.17) | 15 (0.36) | (0) | 813 (1.97) |
 Germany | 2490 (6.78) | 243 (5.76) | 121 (38.54) | 2854 (6.92) |
 Spain | 893 (2.43) | 141 (3.34) | 32 (10.19) | 1066 (2.58) |
 France | 2160 (5.88) | 271 (6.42) | 13 (4.14) | 2444 (5.92) |
 United Kingdom | 2169 (5.91) | 168 (3.98) | 6 (1.91) | 2343 (5.68) |
 Italy | 1791 (4.88) | 204 (4.83) | 54 (17.20) | 2049 (4.97) |
 Japan | 2033 (5.54) | 183 (4.34) | 2 (0.64) | 2218 (5.38) |
 Poland | 638 (1.74) | 55 (1.30) | 35 (11.15) | 728 (1.76) |
 United states | 11,564 (31.50) | 1680 (39.80) | 4 (1.27) | 13,248 (32.12) |
 Other countries | 9040 (24.62) | 871 (20.63) | 29 (9.24) | 9940 (24.10) |
Reporters, n (%) | ||||
 Consumer | 3433 (9.35) | 513 (12.15) | 8 (2.55) | 3954 (9.59) |
 Health-professional | 4681 (12.75) | 569 (13.48) | 24 (7.64) | 5274 (12.79) |
 Lawyer | 266 (0.72) | 228 (5.40) | (0) | 494 (1.20) |
 Physician | 15,609 (42.51) | 1753 (41.53) | 224 (71.34) | 17,586 (42.63) |
 Other health-professional | 8749 (23.83) | 685 (16.23) | 47 (14.97) | 9481 (22.98) |
 Pharmacist | 1626 (4.43) | 237 (5.61) | 10 (3.18) | 1873 (4.54) |
 Unknown | 2351 (6.40) | 236 (5.59) | 1 (0.32) | 2588 (6.27) |
Indications, n (%) | ||||
 Acute leukaemia | 1747 (4.76) | 66 (1.56) | 17 (5.41) | 1830 (4.44) |
  Acute lymphocytic leukaemia | 1187 (67.95) | 25 (37.88) | 17 (100.00) | 1229 (67.16) |
  Other acute leukaemia | 560 (32.05) | 41 (62.12) | (0) | 601 (32.84) |
 Malignant lymphoma | 12,448 (33.90) | 755 (17.89) | 63 (20.06) | 13,266 (32.16) |
  Diffuse large B-cell lymphoma | 4999 (40.16) | 400 (52.98) | 28 (44.44) | 5427 (40.91) |
  B-cell lymphoma | 1773 (14.24) | 47 (6.23) | 9 (14.29) | 1829 (13.79) |
  Non-Hodgkin's lymphoma | 1689 (13.57) | 76 (10.07) | 13 (20.63) | 1778 (13.40) |
  Other lymphoma | 3987 (32.03) | 232 (30.72) | 13 (20.64) | 4232 (31.9) |
Breast cancer | 3787 (10.31) | 400 (9.48) | 170 (54.14) | 4357 (10.56) |
Lung cancer | 89 (0.24) | 11 (0.26) | 1 (0.32) | 101 (0.24) |
Ovarian cancer | 671 (1.83) | 807 (19.12) | 2 (0.64) | 1480 (3.59) |
Sarcoma | 1943 (5.29) | 161 (3.81) | (0) | 2104 (5.10) |
 Osteosarcoma | 345 (17.76) | 19 (11.80) | (0) | 364 (17.30) |
 Ewing's sarcoma | 352 (18.12) | 14 (8.70) | (0) | 366 (17.40) |
 Kaposi's sarcoma | 84 (4.32) | 37 (22.98) | (0) | 121 (5.75) |
 Other sarcoma | 1162 (59.8) | 91 (56.52) | (0) | 1253 (59.55) |
Nephroblastoma | 86 (0.23) | 3 (0.07) | (0) | 89 (0.22) |
Renal cancer | 143 (0.39) | 9 (0.21) | (0) | 152 (0.37) |
Multiple myeloma | 1325 (3.61) | 334 (7.91) | 2(0.64) | 1661 (4.03) |
Other cancer/unkown indication | 14,476 (39.43) | 1675 (39.68) | 59(3.64) | 16,210 (7.03) |
Reporting year, n (%) | ||||
 2004–2007 | 3042 (8.29) | 577 (13.67) | 4 (1.27) | 3623 (8.78) |
 2008–2011 | 4006 (10.91) | 502 (11.89) | 33 (10.51) | 4541 (11.01) |
 2012–2015 | 6721 (18.31) | 626 (14.83) | 134 (42.68) | 7481 (18.14) |
 2016–2019 | 12,164 (33.13) | 1143 (27.08) | 73 (23.25) | 13,380 (32.44) |
 2020–2022 | 10,782 (29.37) | 1373 (32.53) | 70 (22.29) | 12,225 (29.64) |
Sex, n (%) | ||||
 Female | 17,331 (47.20) | 2751 (65.17) | 248 (78.98) | 20,330 (49.28) |
 Male | 12,724 (34.66) | 993 (23.53) | 33 (10.51) | 13,750 (33.33) |
 Unknown | 6660 (18.14) | 477 (11.30) | 33 (10.51) | 7170 (17.38) |
 Total | 36,715 (100.00) | 4221 (100.00) | 314 (100.00) | 41,250 (100.00) |
